🇺🇸 FDA
Patent

US 10001483

Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers

granted A61KA61K31/4035A61K31/454

Quick answer

US patent 10001483 (Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Jun 14 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Jun 19 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 14 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
29
CPC classes
A61K, A61K31/4035, A61K31/454, A61K31/704, A61K45/06